EGFR and neoplasm: Specifically, the addition of bosentan to gefitinib, an EGFR inhibitor, was found to significantly improve tumor perfusion and drug delivery, in addition to successfully reducing tumor size and preventing tumor recurrence compared to treatment with gefitinib alone [106,110].